Pfizer, Bluebird Bio, Inhibrx, and more!

Welcome back everybody, to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And outside of it this week, our next vacation could be in space, so, stick around to learn more. So, to kick things off this week, Pzifer… Read more

Novartis, BioMarin, Iovance, and more!

Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And, this week, can we catch Schrodinger’s cat? Stick around to find out more. But, to kick things off for the industry this week, Novartis has gotten… Read more

Immunomedics, Incyte, uBiome, and more!

Welcome back everybody to another edition of “BioPharma Bitez,” top news in the industry as well as one outside of it. Hint this week, organs coming from the sky? Possibly! So, to kick things off this week, Immunomedics has lost its CMO Rob Iannone this week. This comes months after… Read more

Novartis, Teva, Satsuma, and more!

Welcome back everybody, to another edition of “BioPharma Bitez,” the top news in the industry, as well as one story outside of it. So, to kick things off this week, Novartis has backed Poseida Therapeutics for $142 million for their “BC MA CAR-T” technology, just adding some more R&D to… Read more

Zogenix, Indivior, Scynexis, and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, to kick things off, Regeneron has announced a one billion dollar upfront deal with Alnylam to use its RNA platform for their R&D projects this week. … Read more

NCI, Sanofi, Spectrum, and more!

Welcome back everybody to another edition of “BioPharma Bitez.” The top news in the industry, as well as one story outside of it. Now with even more branding. So, to kick it off this week, the NCI head Ned Sharpless has been named the acting FDA Commissioner this week, which… Read more

BioPharma Bitez: AstraZeneca, Axovant, and more!

Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. So, to kick things off this week, AbbVie has boosted its, “multiple myeloma” program with a new million dollar in “teneobio” who specializes in heavy chain antibodies.… Read more

BioPharma Bitez: Alkermes, Merck, UniQure, and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off, Alkermes says, and LCFD has rejected the NDA for their top-of-the-line depression drug this past week. GSK is now co-developing a fusion protein… Read more

BioPharma Bitez: Roche, Voyage, UK Biotechs and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off in the past week, UK Biotechs had a record year of vesting with over 1.1 billion pounds which is about 1.44 billion dollars vested… Read more

BioPharma Bitez: Celgene, CRISPR, Editas and more!

Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And stick around to for a new segment that I have added on. So, to kick it off this week, Celgene continues their deal-making campaign with Kyn… Read more